logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table GPS-1. Lifetime prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) [see all tables in this series...]

Part (ii) Lifetime prevalence all adults: last survey available for each Member State (from 2000 onwards)

CountryGeographical areaYearReferenceAge range all adultsSample size all adultsCannabis (%)Cocaine (%) (1)Amphetamines (%) (2)Ecstasy (%) (3)LSD (%)
BelgiumNational2004(6)15–64:13.0::::
BulgariaNational2008(3)15–6451397.31.72.11.70.2
Czech RepublicNational2008(3)15–64450034.22.04.39.65.6
DenmarkNational2008(5)16–64340838.64.76.31.91.7
GermanyNational2006(7)18–64791223.02.52.52.01.7
EstoniaNational2008(3)15–641401:::::
IrelandNational2006–07(5)15–64496721.95.33.55.42.9
GreeceNational (except Aegean and Ionian Islands)2004(3)15–6443518.90.70.10.40.3
SpainNational2007-08(7)15–642371527.38.33.84.2:
FranceNational2005(6)15–642587930.62.61.42.01.5
ItalyNational2008(4)15–641094032.07.03.23.0:
CyprusNational2006(1)15–6435046.61.10.81.60.9
LatviaNational2007(2)15–64450012.12.33.34.71.4
LithuaniaNational2008(2)15–64477711.90.51.62.10.4
Luxembourg::::::::::
HungaryNational2007(3)18–6427108.50.91.82.41.1
MaltaNational2001(1)18–6417553.50.40.40.70.5
NetherlandsNational2005(3)15–64451622.63.42.14.31.4
AustriaNational2008(2)15–64376114.22.22.52.31.9
PolandNational2006(2)15–6428599.00.82.71.20.9
PortugalNational2007(2)15–641220211.71.90.91.30.6
RomaniaNational2007(2)15–6467971.50.10.00.30.0
SloveniaNational2007(1)15–641724:::::
SlovakiaNational2006(6)15–64130516.11.21.24.3:
FinlandNational2006(7)15–64280214.31.12.21.61.1
SwedenNational2008(5)15–642209521.43.35.02.1:
SwedenNational2008(10)16-64834311.2::::
United KingdomEngland and Wales2008-09(12)16-592840731.19.412.38.65.5
United KingdomNorthern Ireland2007-08(16)16–64273117.83.95.66.43.5
United KingdomScotland2006(19)16–59315732.98.914.19.97.7
United KingdomUnited Kingdom2006(21)16–59:30.27.711.97.55.6
Croatia::::::::::
Turkey::::::::::
NorwayNational2004(2)15–64266916.22.73.61.81.1

Notes:

 This table presents the methods and results for the last surveys available in each country. The number indicated in the ‘Ref.’ column is the reference to the corresponding survey in the table presenting all surveys available for each country in Table GPS-7. For sources of each survey see Table GPS-0

 (1) Cocaine, any form. 

 (2) For Belgium National 2001 and for Metropolitan France 1995: amphetamine and ecstasy. 

 (3) For Spain: ecstasy and other designer drugs. 

 This table aims to present an overview of national surveys. Exceptionally, some relevant regional surveys are presented. Some city surveys reported by countries were not included as they tend to produce higher prevalence estimates which are not comparable with estimates for whole countries (or large regions with both urban and rural areas). Athens was included as reference point for the 1993 survey.  

 In surveys with small sample sizes results should be interpreted with caution. 

 Countries were asked to report results using, as far as possible, EMCDDA standard age groups (all adults: 15-64, young adults: 15-34). In countries where age ranges are more restrictive, prevalence estimates tend to be slightly higher. Some countries have recalculated their prevalence figures using the EMCDDA standard age groups. 

 For methods and definitions on population surveys in general, see General population surveys of drug use – methods and definitions

 See also 'General notes for interpreting data' on the Explanatory notes and help page

Sources:

 See Table GPS-0

(see the help page for information about formats etc.)

Page last updated: Wednesday, 23 June 2010